Literature DB >> 8188357

Treatment with anti-interleukin-10 monoclonal antibody enhances early resistance to but impairs complete clearance of Listeria monocytogenes infection in mice.

R D Wagner1, N M Maroushek, J F Brown, C J Czuprynski.   

Abstract

Mice that received an anti-interleukin-10 (anti-IL-10) neutralizing monoclonal antibody (MAb) (SXC-1) prior to infection with Listeria monocytogenes initially demonstrated resistance to the infection, as indicated by reduced recovery of L. monocytogenes from their spleens and livers during the first 5 days after challenge. Anti-IL-10 MAb-treated mice then demonstrated reduced resistance during the later stage of infection, as indicated by persistent infection with L. monocytogenes in their livers 11 days after challenge. Aspartate aminotransferase (AST) levels (a measure of liver damage) in the sera of control mice increased between 1 and 5 days after challenge, while anti-IL-10 MAb-treated mice maintained lower AST levels. At 7 days after challenge, AST levels in the sera of control mice decreased as the numbers of organisms declined. In contrast, AST levels increased as the infections persisted in anti-IL-10 MAb-treated mice. The AST levels in serum reflected liver histopathology as anti-IL-10 MAb-treated mice exhibited fewer granulomatous lesions and less necrosis of liver tissue than the control mice during the first 5 days after challenge. Anti-IL-10 MAb treatment altered the expression of inflammatory cytokine mRNAs during L. monocytogenes infection. Control MAb-treated mice exhibited increased expression of tumor necrosis factor alpha and granulocyte-macrophage colony-stimulating factor mRNA in their lives during L. monocytogenes infection, but this increase did not occur in anti-IL-10 MAb-treated mice. Gamma interferon mRNA expression in the livers of the control MAb-treated mice was increased between 1 and 5 days after L. monocytogenes challenge and then decreased at 7 days after challenge. In contrast, gamma interferon mRNA expression in the livers of anti-IL-10 MAb-treated mice was not decreased until 7 days after challenge. These results indicate that endogenous IL-10 has both beneficial and detrimental effects on the host response to L. monocytogenes infection in mice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188357      PMCID: PMC186517          DOI: 10.1128/iai.62.6.2345-2353.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

Review 1.  Functional diversity of T lymphocytes due to secretion of different cytokine patterns.

Authors:  N E Street; T R Mosmann
Journal:  FASEB J       Date:  1991-02       Impact factor: 5.191

2.  Dynamics of lymphocytes and inflammatory cells recruited in liver during murine listeriosis. A cytofluorimetric study.

Authors:  P L Goossens; H Jouin; G Milon
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

3.  Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10.

Authors:  A O'Garra; G Stapleton; V Dhar; M Pearce; J Schumacher; H Rugo; D Barbis; A Stall; J Cupp; K Moore
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

4.  Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay.

Authors:  T R Mosmann; J H Schumacher; D F Fiorentino; J Leverah; K W Moore; M W Bond
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

5.  IL-10 neutralization augments mouse resistance to systemic Mycobacterium avium infections.

Authors:  M Denis; E Ghadirian
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

6.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.

Authors:  D F Fiorentino; A Zlotnik; P Vieira; T R Mosmann; M Howard; K W Moore; A O'Garra
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

7.  Production of tumor necrosis factor during murine listeriosis.

Authors:  E A Havell
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

8.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

9.  Neutrophil-mediated dissolution of infected host cells as a defense strategy against a facultative intracellular bacterium.

Authors:  J W Conlan; R J North
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

10.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.

Authors:  R de Waal Malefyt; J Abrams; B Bennett; C G Figdor; J E de Vries
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

View more
  30 in total

1.  Dietary supplementation with conjugated linoleic acid does not alter the resistance of mice to Listeria monocytogenes infection.

Authors:  L Turnock; M Cook; H Steinberg; C Czuprynski
Journal:  Lipids       Date:  2001-02       Impact factor: 1.880

2.  Sex-dependent susceptibility to Listeria monocytogenes infection is mediated by differential interleukin-10 production.

Authors:  Bastian Pasche; Svetoslav Kalaydjiev; Tobias J Franz; Elisabeth Kremmer; Valérie Gailus-Durner; Helmut Fuchs; Martin Hrabé de Angelis; Andreas Lengeling; Dirk H Busch
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Th0-like CD4+ T cells protect mice with murine retrovirus-induced immunodeficiency syndrome (MAIDS) against co-infection with Listeria monocytogenes.

Authors:  K Hiromatsu; H Nishimura; K Kimura; Y Aoki; J Usami; N Kobayashi; M Makino; Y Yoshikai
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

4.  The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene.

Authors:  Zhiyu Li; John Fallon; John Mandeli; James Wetmur; Savio L C Woo
Journal:  Hum Gene Ther       Date:  2009-07       Impact factor: 5.695

5.  Gamma interferon and interleukin-10 gene expression in innately susceptible and resistant mice during the early phase of Salmonella typhimurium infection.

Authors:  S Pie; P Matsiota-Bernard; P Truffa-Bachi; C Nauciel
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

6.  Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice.

Authors:  T Matsumoto; K Tateda; S Miyazaki; N Furuya; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Tumor necrosis factor-α, monocyte chemoattractant protein-1 and intercellular adhesion molecule-1 increase during the development of a 2,4-dinitrofluorobenzene-induced immediate-type dermatitis in rats.

Authors:  Guangchen Sun; Yaqin Wang; Bo Yin; Lingjin Zhu; Yingqin Liu
Journal:  Inflamm Res       Date:  2013-03-26       Impact factor: 4.575

8.  Effects of in vivo administration of anti-IL-10 monoclonal antibody on the host defence mechanism against murine Salmonella infection.

Authors:  T Arai; K Hiromatsu; H Nishimura; Y Kimura; N Kobayashi; H Ishida; Y Nimura; Y Yoshikai
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

9.  IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge.

Authors:  K Kai McKinstry; Tara M Strutt; Amanda Buck; Jonathan D Curtis; John P Dibble; Gail Huston; Michael Tighe; Hiromasa Hamada; Stewart Sell; Richard W Dutton; Susan L Swain
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

10.  IL-10 signaling blockade controls murine West Nile virus infection.

Authors:  Fengwei Bai; Terrence Town; Feng Qian; Penghua Wang; Masahito Kamanaka; Tarah M Connolly; David Gate; Ruth R Montgomery; Richard A Flavell; Erol Fikrig
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.